Find Quinidine Gluconate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

JP

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

91 RELATED EXCIPIENT COMPANIES

160EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Duraquin, 7054-25-3, Gluquinate, Dura-tab, Quinidine mono-d-gluconate, 6587-33-3
Molecular Formula
C26H36N2O9
Molecular Weight
520.6  g/mol
InChI Key
XHKUDCCTVQUHJQ-LCYSNFERSA-N
FDA UNII
R6875N380F

Quinidine Gluconate
Quinidine Gluconate is the gluconate salt form of quinidine, an alkaloid with antimalarial and antiarrhythmic (Class la) properties. Quinidine gluconate exerts its anti-malarial activity by acting primarily as an intra-erythrocytic schizonticide through association with the hemepolymer (hemozoin) in the acidic food vacuole of the parasite thereby preventing further polymerization by heme polymerase enzyme. This results in accumulation of toxic heme and death of the parasite. Quinidine gluconate exerts its antiarrhythmic effects by depressing the flow of sodium ions into cells during phase 0 of the cardiac action potential, thereby slowing the impulse conduction through the atrioventricular (AV) node, reducing the maximal rate of phase 0 depolarization and prolonging the refractory period. Quinidine gluconate also reduces the slope of phase 4 depolarization in Purkinje-fibres resulting in slowed conduction and reduced automaticity in the heart.
1 2D Structure

Quinidine Gluconate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid
2.1.2 InChI
InChI=1S/C20H24N2O2.C6H12O7/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;7-1-2(8)3(9)4(10)5(11)6(12)13/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;2-5,7-11H,1H2,(H,12,13)/t13-,14-,19+,20-;2-,3-,4+,5-/m01/s1
2.1.3 InChI Key
XHKUDCCTVQUHJQ-LCYSNFERSA-N
2.1.4 Canonical SMILES
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O.C(C(C(C(C(C(=O)O)O)O)O)O)O
2.1.5 Isomeric SMILES
COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O
2.2 Other Identifiers
2.2.1 UNII
R6875N380F
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Quinact

2. Quinaglute

3. Quinidine Gluconate, (8alpha,9r)-isomer

4. Quinidine Gluconate, (9s)-isomer

2.3.2 Depositor-Supplied Synonyms

1. Duraquin

2. 7054-25-3

3. Gluquinate

4. Dura-tab

5. Quinidine Mono-d-gluconate

6. 6587-33-3

7. Nsc-757297

8. Gluconic Acid Quinidine Salt

9. Quinidine Monogluconate, D-

10. Chebi:27502

11. R6875n380f

12. Quinidine Gluconate Salt

13. Cinchonan-9-ol, 6'-methoxy-, (9s)-, Mono-d-gluconate (salt)

14. D-gluconic Acid, Compd. With (9s)-6'-methoxycinchonan-9-ol (1:1)

15. Quinidine Gluconate [usp]

16. (s)-[(2r,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic Acid

17. Quinidine D-gluconate

18. Sr-05000001710

19. Quinidine, D-gluconate (salt)

20. Unii-r6875n380f

21. Quinidine Mono-d-gluconate (salt)

22. Einecs 229-517-1

23. Einecs 230-333-9

24. Spectrum_000910

25. Spectrum2_000408

26. Spectrum3_000893

27. Spectrum4_000987

28. Spectrum5_001080

29. Schembl41479

30. Kbiogr_001393

31. Kbioss_001390

32. Divk1c_000228

33. Spectrum1500523

34. Spbio_000336

35. Chembl1200437

36. Quinidine Gluconate [mi]

37. Schembl15541190

38. Hms500l10

39. Hy-b1751f

40. Kbio1_000228

41. Kbio2_001390

42. Kbio2_003958

43. Kbio2_006526

44. Kbio3_001806

45. Ninds_000228

46. Dtxsid801027497

47. Hms1920n18

48. Hms2092e19

49. Pharmakon1600-01500523

50. Quinidine Gluconate [vandf]

51. D-gluconic Acid, Compound With (9s)-6'-methoxycinchonan-9-ol

52. Quinidine Gluconate [mart.]

53. Ccg-38674

54. Nsc757297

55. Quinidine Gluconate [usp-rs]

56. Quinidine Gluconate [who-dd]

57. Ex-6000

58. Nsc 757297

59. Idi1_000228

60. Quinidine Gluconate [orange Book]

61. Quinidine Gluconate [usp Monograph]

62. Cs-0030857

63. Quinidine Gluconate Salt, Analytical Standard

64. 054q253

65. Gluconic Acid, Compd. With Quinidine (1:1), D-

66. Sr-05000001710-1

67. Sr-05000001710-2

68. W-110193

69. Q27094388

70. (9s)-6'-methoxycinchonan-9-ol--d-gluconic Acid (1:1)

71. Cinchonan-9-ol, 6'-methoxy-, (9s)-, Mono-d-gluconate

72. D-gluconic Acid, Compd. With (9s)-6'-methoxycinchonan-9-ol (1:?)

73. Quinidine Gluconate, United States Pharmacopeia (usp) Reference Standard

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 520.6 g/mol
Molecular Formula C26H36N2O9
Hydrogen Bond Donor Count7
Hydrogen Bond Acceptor Count11
Rotatable Bond Count9
Exact Mass520.24208073 g/mol
Monoisotopic Mass520.24208073 g/mol
Topological Polar Surface Area184 Ų
Heavy Atom Count37
Formal Charge0
Complexity627
Isotope Atom Count0
Defined Atom Stereocenter Count8
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antimalarials

Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)


4.2 FDA Pharmacological Classification
4.2.1 Pharmacological Classes
Cytochrome P450 2D6 Inhibitor [EPC]; Cytochrome P450 2D6 Inhibitors [MoA]; Antiarrhythmic [EPC]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Co-Processed Excipients

read-more
read-more

Granulation

read-more
read-more

Lubricants & Glidants

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Controlled & Modified Release

read-more
read-more

Solubilizers

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Coating Systems & Additives

read-more
read-more

Taste Masking

read-more
read-more

Emulsifying Agents

read-more
read-more

Parenteral

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Rheology Modifiers

read-more
read-more

API Stability Enhancers

read-more
read-more

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty